Andrea Schietinger, PhD, to Present 2023 AACR-Irving Weinstein Foundation Distinguished Lecture
PHILADELPHIA — The American Association for Cancer Research (AACR) will award the 19th AACR-Irving Weinstein Foundation Distinguished Lectureship to...
Search/Filter
Loading...
Breast-conserving Therapy May be a Treatment Option for Some Patients with Multiple Breast Lesions
SAN ANTONIO – Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy...
Genetic Profiling May Identify Patients with Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-conserving Surgery
SAN ANTONIO – Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had...
Adding Capivasertib to Fulvestrant Improves Progression-free Survival in Patients With Advanced Hormone Receptor-positive Breast Cancer
SAN ANTONIO – In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational...
Treatment Decision Guided by Circulating Tumor Cell Count May Improve Long-term Outcomes for Patients with Metastatic Breast Cancer
SAN ANTONIO – The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine...
Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor-positive, HER2-negative Breast Cancer
SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
Breast Cancer Patients Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-term Recurrence Rates
Most were able to conceive and more than 60 percent gave birth SAN ANTONIO – Breast cancer patients who...
T-DXd Yields Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously Treated with T-DM1
SAN ANTONIO – Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in...
T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2-positive Metastatic Breast Cancer
SAN ANTONIO – Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine...
Neoadjuvant Trastuzumab Deruxtecan Shows Clinical Activity in Patients With HER2-low Breast Cancer
SAN ANTONIO – Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the...